scholarly journals Original article Clinical and neuroimaging correlation of movement disorders in multiple sclerosis: case series and review of the literature

2014 ◽  
Vol 1 ◽  
pp. 92-100 ◽  
Author(s):  
Anna Potulska-Chromik ◽  
Monika Rudzinska ◽  
Monika Nojszewska ◽  
Aleksandra Podlecka-Piętowska ◽  
Andrzej Szczudlik ◽  
...  
2010 ◽  
Vol 14 (4) ◽  
pp. 151-155 ◽  
Author(s):  
Tiffany Kwok ◽  
Wei Jing Loo ◽  
Lyn Guenther

Background: Psoriasis and multiple sclerosis (MS) are both autoimmune T cell-mediated diseases. Some case series have suggested an association. Objective: To investigate the potential relationship between psoriasis and MS based on a systematic review of the literature. Methods: Medline, Cochrane Library, and EMBASE searches were performed. Results: T-helper 17 cells are involved in the pathogenesis of both psoriasis and MS. Both conditions have been associated with interleukin-23 receptor (IL23R) polymorphisms. Studies have reported psoriasis in 0.41 to 7.7% of individuals with MS. A higher rate of psoriasis compared to controls was noted in a few small MS cohorts, but the number of cases was too small to draw any firm conclusions. In two studies, including a large Canadian study of 5,031 patients with MS, there was no increased prevalence of psoriasis in patients over the control population. Family members of individuals with MS do not appear to be at increased risk for psoriasis in these studies. Psoriasis has developed during treatment for MS, and MS has developed during treatment for psoriasis. Conclusion: Although there are some common genetic linkages in psoriasis and MS, psoriasis does not appear to be more common in patients with MS or their relatives.


2015 ◽  
Vol 263 (3) ◽  
pp. 422-427 ◽  
Author(s):  
Lorenzo Gaetani ◽  
Paola S. Menduno ◽  
Francesco Cometa ◽  
Maria Di Gregorio ◽  
Paola Sarchielli ◽  
...  

2008 ◽  
Vol 10 (2) ◽  
pp. 41-46 ◽  
Author(s):  
Douglas A. Woo ◽  
Robert H. Collins ◽  
Howard S. Rossman ◽  
Olaf Stüve ◽  
Elliot M. Frohman

This article describes four new cases from our clinical practices of therapy-related acute leukemia after use of mitoxantrone in the treatment of patients with multiple sclerosis (MS) and reviews the mechanisms that predispose to this serious complication of treatment. The study consisted of a retrospective case series. Four previously unreported cases of secondary leukemia arising after mitoxantrone therapy in MS patients were identified, out of a combined cohort of 152 patients treated at our institutions. Three of the patients developed the acute promyelocytic leukemia subtype, after varying doses and latencies of mitoxantrone therapy. One of the study patients died. Characteristics of these patients and 10 previously reported cases are summarized. MS patients treated with mitoxantrone remain at risk for therapy-related leukemia, particularly acute promyelocytic leukemia. Strategies for minimization and prompt identification of this adverse event are needed.


2018 ◽  
Vol 56 (01) ◽  
pp. E2-E89
Author(s):  
D Reher ◽  
C Schramm ◽  
F Brinkert ◽  
A Lohse ◽  
C Weiler-Normann

2019 ◽  
Vol 81 (1) ◽  
pp. 14-17
Author(s):  
Yuka KUNIMI ◽  
Yasunori OHGA ◽  
Kotaro ITO ◽  
Shinichi HIROSE ◽  
Shinichi IMAFUKU

Sign in / Sign up

Export Citation Format

Share Document